GILD Oct 2024 83.000 call
| Previous Close | 1.3200 |
| Open | 1.2500 |
| Bid | 1.5300 |
| Ask | 1.6900 |
| Strike | 83.00 |
| Expire Date | 2024-10-04 |
| Day's Range | 1.1000 - 1.5300 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 220 |
Business WireGilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
FOSTER CITY, Calif., October 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people.
Simply Wall St.Gilead Sciences' (NASDAQ:GILD) investors will be pleased with their favorable 62% return over the last five years
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...
ZacksPraxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
